EGFR and neoplasm: In our study and motivated by our previous research [17], we linked histological morphology and molecular pathology in anti‐EGFR treatment by analysing mutational profiles of tumour regions (consisting of selected morphotypes, invasion front and whole‐tumour sections) of the early‐ and late‐progressing patients.